The clinical efficacy of trastuzumab in patients with HER2 over-expressing tumors has clearly demonstrated the possibility to impact on disease progression through immunotherapy and encourages the development of anti-cancer vaccines in breast cancer, provided that appropriate target tumor antigens and patient groups are identified. This evidence concerns the gene ERBB2 and cancer.